Linda Lennox - Lantheus Holdings VP Staff
| LNTH Stock | USD 90.52 3.20 3.66% |
Insider
Linda Lennox is VP Staff of Lantheus Holdings
| Age | 58 |
| Address | 201 Burlington Road, Bedford, MA, United States, 01730 |
| Phone | 978 671 8001 |
| Web | https://www.lantheus.com |
Lantheus Holdings Management Efficiency
The company has return on total asset (ROA) of 0.17 % which means that it generated a profit of $0.17 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4553 %, meaning that it created $0.4553 on every $100 dollars invested by stockholders. Lantheus Holdings' management efficiency ratios could be used to measure how well Lantheus Holdings manages its routine affairs as well as how well it operates its assets and liabilities. The Lantheus Holdings' current Return On Tangible Assets is estimated to increase to 0.24. The Lantheus Holdings' current Return On Capital Employed is estimated to increase to 0.26. As of now, Lantheus Holdings' Net Tangible Assets are increasing as compared to previous years. The Lantheus Holdings' current Return On Tangible Assets is estimated to increase to 0.24, while Non Current Assets Total are projected to decrease to under 376.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Penny Wan | Dr Reddys Laboratories | N/A | |
| Daryl Gaugler | Pacira BioSciences, | 62 | |
| Floyd MD | Alkermes Plc | 87 | |
| Erez MBA | Dr Reddys Laboratories | 56 | |
| Jude Onyia | Neurocrine Biosciences | 60 | |
| Gunupati BE | Dr Reddys Laboratories | 64 | |
| Joel Morales | Alvotech Warrant | 46 | |
| Christian PharmD | Avadel Pharmaceuticals PLC | N/A | |
| Steven Sullivan | Avadel Pharmaceuticals PLC | 59 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Michael Grippo | Catalent | 55 | |
| Jordan MD | Avadel Pharmaceuticals PLC | 46 | |
| CPA CPA | Journey Medical Corp | 69 | |
| Ernest Galvan | Journey Medical Corp | 62 | |
| Sean Gaskell | Alvotech Warrant | 42 | |
| Anil Okay | Alvotech Warrant | 38 | |
| P Yugandhar | Dr Reddys Laboratories | 49 | |
| Claude Maraoui | Journey Medical Corp | 57 | |
| Kenneth MD | Aquestive Therapeutics | N/A | |
| John Minardo | Ironwood Pharmaceuticals | 48 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
Management Performance
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.17 |
Lantheus Holdings Leadership Team
Elected by the shareholders, the Lantheus Holdings' board of directors comprises two types of representatives: Lantheus Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lantheus. The board's role is to monitor Lantheus Holdings' management team and ensure that shareholders' interests are well served. Lantheus Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lantheus Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lee Howe, Chief Officer | ||
| Daniel Niedzwiecki, General Officer | ||
| Dorothy Barr, Senior Operations | ||
| Paul Blanchfield, Chief Officer | ||
| Amanda Morgan, Senior Commercial | ||
| Etienne Montagut, Senior Vice President - Corporate Development | ||
| Carol Walker, Vice President | ||
| Brian Markison, Non-Executive Independent Chairman | ||
| Mark Kinarney, Director Relations | ||
| CFA Marshall, Chief Officer | ||
| Jamie Spaeth, Chief Officer | ||
| Melissa Downs, Director Communications | ||
| Linda Lennox, VP Staff | ||
| Mary Heino, CEO and President and Director | ||
| JeanClaude MD, Chief Officer | ||
| Andrea Sabens, Chief Officer | ||
| Kimberly Brown, Chief Officer |
Lantheus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lantheus Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.29 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 6.05 B | ||||
| Shares Outstanding | 69.53 M | ||||
| Shares Owned By Insiders | 2.47 % | ||||
| Shares Owned By Institutions | 97.53 % | ||||
| Number Of Shares Shorted | 4.19 M | ||||
| Price To Earning | 36.43 X |
Currently Active Assets on Macroaxis
When determining whether Lantheus Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantheus Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantheus Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantheus Holdings Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantheus Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Lantheus Stock please use our How to Invest in Lantheus Holdings guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantheus Holdings. If investors know Lantheus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantheus Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Earnings Share 6.02 | Revenue Per Share 21.687 | Quarterly Revenue Growth 0.184 | Return On Assets 0.17 |
The market value of Lantheus Holdings is measured differently than its book value, which is the value of Lantheus that is recorded on the company's balance sheet. Investors also form their own opinion of Lantheus Holdings' value that differs from its market value or its book value, called intrinsic value, which is Lantheus Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantheus Holdings' market value can be influenced by many factors that don't directly affect Lantheus Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantheus Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantheus Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantheus Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.